30 Day Trial
BARE BONES logo

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

DiscGenics Receives FDA Fast Track Designation for Cell Therapy -

DiscGenics was granted Fast Track designation from FDA for its investigational cell therapy, IDCT, under evaluation in clinical trials in the U.S. and Japan to treat pain and disability from degenerative disc disease. Companies can apply for Fast Track once they have sufficient preclinical and clinical evidence that a product may be able to treat an unmet medical need for a serious medical condition. Enrollment is ongoing in the two clinical trials. IDCT is being evaluated in the U.S. under an investigational new drug allowance by FDA, and will be regulated as a drug/biologic through a biologics license application. In Japan, the trial is supported by a Clinical Trial Notification approved by the Japanese Pharmaceuticals and Medical Devices Agency. The U.S. study has shown safety in the first cohort of patients. (DiscGenics, 8/26/19)